edf壹定发

全体研究组长

王跃祥
博士 研究员 博士生导师

中科院肿瘤与微环境重点实验室,“肿瘤演变与转化医学”课题组组长

研究方向:消化道肿瘤恶性演变的分子机制及治疗策略

电子邮件(E-mail):yxwang76@sibs.ac.cn

电话(Tel):86-21-54923278

邮政编码:200031

简历 & 研究方向
2017-至     今:edf壹定发 研究员
2015-2016年:edf壹定发上海生命科学研究院/上海交通大学医学院健康科学研究所-上海长征医院联合转化医学中心 研究员
2007-2015年:美国哈佛大学医学院/布莱根妇女医院病理系博士后、高级研究科学家、讲师
1999-2007年:复旦大学上海医学院分子医学教育部重点实验室助教、讲师、副教授
2001-2007年:复旦大学上海医学院, 生物化学与分子生物学, 博士
1994-1999年:上海医科大学, 药理学, 学士

研究方向
肿瘤是一类由基因突变导致的遗传性疾病,本实验室主要解析人类恶性肿瘤演变的分子遗传学机制,为这些致死性肿瘤的早期诊断和治疗提供新型策略。主要的研究方向有:
1. 肉瘤(间叶细胞来源恶性肿瘤)演变的分子机制;
2. 癌(上皮细胞来源恶性肿瘤)演变的分子机制;
3. 整合基因组大数据分析;
4. 新型诊断试剂及抗肿瘤药物的研制。

代表性论文(* 通讯编辑)

  1. Li Z#, Shao C#, Liu X, Lu X, Jia X, Zheng X, Wang S, Zhu L, Li K, Pang Y, Xie F, Lu Y, Wang Y*. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis. 2019 May 2. doi: 10.1093/carcin/bgz086.
  2. Wang YX, Mari?o-Enriquez A, Bennett RR, Zhu MJ, Shen YP, Eilers G, Lee JC, Fletcher BS, Gu ZZ, Fox EA, Antonescu CR, Fletcher CDM, Guo XQ, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics (IF: 31.616), 2014;46(6):601-606. (highlighted by “Laboratory Investigation”, “Modern Pathology” and “BioWorld Today”, featured in “Cancer Discovery” Research Watch and selected as one of the most popular stories on nature.com)
  3. Serrano C#, Wang YX#, Mari?o-Enriquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GIST: Relevance of concomitant PI3K/AKT dysregulation. Journal of Clinical Oncology (IF: 24.008), 2015;33(22):e93-96. (# Both authors contributed equally)
  4. Wang YX*, Fletcher JA*. Cell cycle and dystrophin dysregulation in GIST. Cell Cycle, 2015;14(17):2713-2714.
  5. Li K#, Cheng HB#, Li Z, Pang YZ, Jia XN, Xie FF, Hu GH, Cai QP*, Wang YX*. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget, 2017, 8(36): 60589-60604.
  6. Wei ZR#, Liang C#, Feng D#, Cheng YJ, Wang WM, Yang DJ, Wang YX*, Cai QP*. Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Oncotarget, 2016;7(14):17737-17750.
  7. Heinrich M, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors. Clinical Sarcoma Research. 2019 Mar 5;9:3. doi:10.1186/s13569-019-0112-7. eCollection 2019.
  8. Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mari?o-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications. 2017;8:14674. doi: 10.1038/ncomms14674.
  9. Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of Insulin Receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Research. 2017;77(18):5107-5117.
  10. Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J, Liu Q. Discovery of N-(3-((1- Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide(CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. 2016;59(8):3964-3979.
  11. Maynard MA, Mari?o-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA, Frates MC, Song H, Jugo RH, Taguchi T, Hershman JM, Larsen PR, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. New England Journal of Medicine. 2014;370(14):1327-1334.
  12. Mari?o-Enríquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014;33(14):1872-1876.
  13. Lynn M, Wang Y, Slater J, Shah N, Conroy J, Ennis S, Morris T, Betts DR, Fletcher JA, O'Sullivan MJ. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagnostic Molecular Pathology. 2013;22(2):76-84.
  14. Ravegnini G, Mari?o-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR,George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Modern Pathology. 2013;26(5):743-749.
  15. Lee CH, Ou WB, Mari?o-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM,McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012;109(3):929-934.
  16. Wang YX, Qian LX, Dong YX, Yao LL, Gui YH, Zhong TP, Song HY. Bone Morphogenetic Protein-2 acts upstream of Myocyte-specific Enhancer Factor 2A to control embryonic cardiac contractility. Cardiovascular Research, 2007;74(2):290-303.
  17. Wang YX, Qian LX, Jiang Q, Dong YX, Gui YH, Zhong TP, Song HY. Myocyte-specific enhancer factor 2A is essential for zebrafish posterior somite development. Mechanisms of Development, 2006;123(10):783-791.
  18. Wang YX, Qian LX, Yu Z, Jiang Q, Dong YX, Liu XF, Yang XY, Zhong TP, Song HY. Requirements of myocyte-specific enhancer factor 2A in zebrafish cardiac contractility. FEBS Letters, 2005;579(21):4843-4850.
  19. Wang Y, Zhong T, Qian L, Dong Y, Jiang Q, Tan L, Song H. Wortmannin induces zebrafish cardia bifida through a mechanism independent of phosphoinositide 3-kinase and myosin light chain kinase. Biochemical and Biophysical Research Communications, 2005;331(1):303-308 (Cover Photo).
  20. Wang YX, Song HY. Developmental genetics of zebrafish cardiovascular systems. Foreign Medical Sciences (Section of Genetics), 2004;27(4):220-223.
  21. Wang YX, Yang J, Ma CG, Yang XY, Song HY. VEGF121 cDNA gene transfer and expression in Vitro. Progress in Biochemistry and Biophysics, 2003;30(4):612-616.
  22. Wang YX, Guan XQ, Yang J, Mo W, Song HY. Molecular Cloning, Expression and characterization of recombinant human vascular endothelial growth factor 121. Progress in Biochemistry and Biophysics, 2002;29(3):444-448.
XML 地图 | Sitemap 地图